Treatment News : Shorter Treatment for Acute Hep C Works in HIV-Coinfected MSM

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 1, 2011

Shorter Treatment for Acute Hep C Works in HIV-Coinfected MSM

HIV-positive men who have sex with men (MSM) diagnosed with acute hepatitis C virus (HCV) infection are just as likely to clear their HCV with a 24-week course of treatment as those treated for a full 48 weeks, according to a report published online May 25 in AIDS.

A new epidemic of HCV infections among MSM living with HIV has emerged and continued to grow during the past 10 years. Currently this epidemic is isolated mostly to urban areas in Western Europe, the United States and Australia, and it has a new twist: Most of the HCV infections are associated with sexual behaviors and not injection drug use.

Public agencies now recommend regular HCV screening in HIV-positive MSM and also suggest that providers pay close attention to the early signs of acute HCV infection, such as a sudden spike in key liver enzymes. Because of these stepped up surveillance methods, more and more HCV infections are being caught during the acute phase, which is within the first several months after HCV is transmitted.

This is good news, as HCV treatment is about three times more successful in people in the acute stage of infection, compared with those who aren’t diagnosed until after the acute phase has passed. What remains unsettled, however, is whether the course of HCV treatment in acutely infected individuals needs to be the full 48 weeks recommended for people who are chronically coinfected with both HIV and HCV, or whether treatment can be administered for half as long.

To determine the answer to this question, Femke Lambers, MD, from the Department of Research at the Public Health Service of Amsterdam, and her colleagues compared 24 weeks of standard HCV treatment (pegylated interferon combined with weight-based dosing of ribavirin) with 48 weeks of standard treatment in HIV-positive MSM with acute HCV infection. Of the 50 who were followed, 21 were slated to receive 24 weeks of treatment and 29 to receive 48 weeks. The two groups were similar in most respects, but the actual course of treatment was at times a little shorter or longer than intended for both groups.

Ultimately, Lambers and her team found that the duration of HCV treatment had no significant effect on whether the men maintained undetectable HCV levels for 24 weeks after completing their course of HCV treatment. This is known as a sustained virological response (SVR), and experts generally accept that an SVR is equivalent to being cured of HCV.

Overall, the SVR rate of 76 percent was about three times higher than is typically observed in individuals with chronic infection undergoing HCV therapy, confirming that catching and treating people during the acute phase is highly desirable. Though the cure rate was higher in those who received 48 weeks of treatment—79 percent versus 71 percent—this difference was small enough that it could have occurred by chance.

“This suggests that 24 weeks of treatment might be sufficient,” the authors comment. “The shorter regimen would be of great advantage for patients, since both peginterferon and ribavirin can cause serious side effects.”

The authors also concluded by observing that neither the participants’ CD4 count, nor their HIV treatment appeared to affect whether they achieved an SVR, and they recommended that subsequent studies should explore this further.

Search: HCV, hepatitis C, acute hepatitis C, MSM, gay, bisexual, coinfection, pegylated interferon, ribavirin, weight-based, Femke Lambers, Public Health Service, Amsterdam

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.